Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer

Background The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (LA/MBC)....

Full description

Bibliographic Details
Main Authors: Robertson, John F.R., Cheung, Kwok-Leung, Noguchi, Shinzaburo, Shao, Zhimin, Degboe, Arnold, Lichfield, Jasmine, Thirlwell, Jackie, Fazal, Mehdi, Ellis, Matthew J.
Format: Article
Published: Elsevier 2018
Subjects:
Anastrozole; FALCON; Fulvestrant; Health-related quality of life; Locally advanced or metastatic breast cancer
Online Access:https://eprints.nottingham.ac.uk/50821/

Internet

https://eprints.nottingham.ac.uk/50821/

Similar Items